Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Preferred Stock Liabilities (2016 - 2018)

Historic Preferred Stock Liabilities for Alaunos Therapeutics (TCRT) over the last 3 years, with Q3 2018 value amounting to $160.4 million.

  • Alaunos Therapeutics' Preferred Stock Liabilities rose 1536.26% to $160.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was $160.4 million, marking a year-over-year increase of 1536.26%. This contributed to the annual value of $144.0 million for FY2017, which is 1489.85% up from last year.
  • As of Q3 2018, Alaunos Therapeutics' Preferred Stock Liabilities stood at $160.4 million, which was up 1536.26% from $154.4 million recorded in Q2 2018.
  • Over the past 5 years, Alaunos Therapeutics' Preferred Stock Liabilities peaked at $160.4 million during Q3 2018, and registered a low of $121.8 million during Q3 2016.
  • For the 3-year period, Alaunos Therapeutics' Preferred Stock Liabilities averaged around $139.8 million, with its median value being $139.1 million (2017).
  • Per our database at Business Quant, Alaunos Therapeutics' Preferred Stock Liabilities surged by 1416.36% in 2017 and then skyrocketed by 1536.26% in 2018.
  • Quarter analysis of 3 years shows Alaunos Therapeutics' Preferred Stock Liabilities stood at $125.3 million in 2016, then rose by 14.9% to $144.0 million in 2017, then grew by 11.42% to $160.4 million in 2018.
  • Its last three reported values are $160.4 million in Q3 2018, $154.4 million for Q2 2018, and $149.0 million during Q1 2018.